检索结果 - Luigi Gargiulo

Refine Results
  1. 1
    Real-Life Effectiveness and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center 16-Week Study

    Real-Life Effectiveness and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center 16-Week Study 由 Luigi Gargiulo, Luciano Ibba, Andrea Cortese, Jessica Avagliano, Mario Valenti, Antonio Costanzo, Alessandra Narcisi

    出版 2023
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series

    Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series 由 Luigi Gargiulo, Luciano Ibba, Giulia Pavia, Jessica Avagliano, Andrea Cortese, Antonio Costanzo, Alessandra Narcisi

    出版 2023
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study

    Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study 由 Luciano Ibba, Luigi Gargiulo, Ângela Alfano, Ruggero Cascio Ingurgio, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

    出版 2023
    获取全文
    Carta
    加到收藏夹
    Saved in:
  4. 4
    Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience

    Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience 由 Luigi Gargiulo, Luciano Ibba, Carlo Alberto Vignoli, Paola Facheris, Mario Valenti, Antonio Costanzo, Alessandra Narcisi

    出版 2023
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review

    Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review 由 Luciano Ibba, Luigi Gargiulo, Carlo Alberto Vignoli, Giovanni Fiorillo, Mario Valenti, Antonio Costanzo, Alessandra Narcisi

    出版 2024
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  6. 6
    Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study

    Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study 由 Luciano Ibba, S. Di Giulio, Luigi Gargiulo, Paola Facheris, Chiara Perugini, Antonio Costanzo, Alessandra Narcisi, Mario Valenti

    出版 2024
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    Effectiveness and safety of upadacitinib for moderate‐to‐severe atopic dermatitis in a real‐world setting: A 52‐week retrospective study

    Effectiveness and safety of upadacitinib for moderate‐to‐severe atopic dermatitis in a real‐world setting: A 52‐week retrospective study 由 Luigi Gargiulo, Luciano Ibba, Francesco Piscazzi, A. Alfano, Ruggero Cascio Ingurgio, Mario Valenti, Antonio Costanzo, Alessandra Narcisi

    出版 2023
    获取全文 获取全文
    Carta
    加到收藏夹
    Saved in:
  8. 8
    Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID‐19 vaccine, successfully treated with risankizumab

    Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID‐19 vaccine, successfully treated with risankizumab 由 Giulia Pavia, Luigi Gargiulo, Francesca Romana Spinelli, Jessica Avagliano, Mario Valenti, Riccardo G. Borroni, Antonio Costanzo, Alessandra Narcisi

    出版 2022
    获取全文
    Carta
    加到收藏夹
    Saved in:
  9. 9
    Impact of delay in follow‐up due to COVID‐19 pandemic on skin cancer progression: a real‐life experience from an Italian hub hospital

    Impact of delay in follow‐up due to COVID‐19 pandemic on skin cancer progression: a real‐life experience from an Italian hub hospital 由 Mario Valenti, Giulia Pavia, Luigi Gargiulo, Paola Facheris, Ombretta Nucca, Luca Mancini, Francesco Sacrini, Riccardo G. Borroni, Alessandra Narcisi, Antonio Costanzo

    出版 2021
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  10. 10
    Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study

    Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study 由 Luigi Gargiulo, Luciano Ibba, Giulia Pavia, Carlo Alberto Vignoli, Francesco Piscazzi, Mario Valenti, Federica Sanna, Chiara Perugini, Jessica Avagliano, Antonio Costanzo, Alessandra Narcisi

    出版 2022
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  11. 11
    Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study

    Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study 由 Luigi Gargiulo, Luciano Ibba, Matteo Bianco, S. Di Giulio, Alfano Alfano, Ruggero Cascio Ingurgio, Paola Facheris, Chiara Perugini, Mario Valenti, Antonio Costanzo, Alessandra Narcisi

    出版 2024
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  12. 12
    Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers

    Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers 由 Diego Orsini, Luigi Gargiulo, Luciano Ibba, Ruggero Cascio Ingurgio, Mario Valenti, Chiara Perugini, Alessia Pacifico, Fabio Stefano Maramao, Pasquale Frascione, Antonio Costanzo, Alessandra Narcisi

    出版 2023
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  13. 13
    Effectiveness of ixekizumab for the treatment of moderate‐to‐severe plaque psoriasis with involvement of difficult‐to‐treat areas: A 52‐week multicenter retrospective study

    Effectiveness of ixekizumab for the treatment of moderate‐to‐severe plaque psoriasis with involvement of difficult‐to‐treat areas: A 52‐week multicenter retrospective study... 由 Mario Valenti, Luigi Gargiulo, Luciano Ibba, Andrea Cortese, Francesco Toso, Diego Orsini, Viviana Lora, Pasquale Frascione, Paolo Sena, Andrea Carugno, Chiara Assorgi, Antonio Costanzo, Alessandra Narcisi

    出版 2024
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  14. 14
    Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study

    Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study 由 Riccardo G. Borroni, Piergiorgio Malagoli, Luigi Gargiulo, Mario Valenti, Giulia Pavia, Paola Facheris, Emanuela Morenghi, Isotta Giunipero di Corteranzo, Alessandra Narcisi, Michela Ortoncelli, Paolo Dapavo, Antonio Costanzo

    出版 2021
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  15. 15
    Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus

    Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus 由 Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, A. Burroni, Andrea Chiricozzi, Paolo Dapavo, Silvia Mariel Ferrucci, Massimo Gola, Maddalena Napolitano, Michela Ortoncelli, Mariateresa Rossi, Claudio Sciarrone, Antonio Costanzo, Alessandra Narcisi

    出版 2024
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  16. 16
    New and Emerging Biologics and Jak Inhibitors for the Treatment of Prurigo Nodularis: A Narrative Review

    New and Emerging Biologics and Jak Inhibitors for the Treatment of Prurigo Nodularis: A Narrative Review 由 M.A. Bianco, F D’Oria, Costanza Falcidia, Giulio Foggi, Elena Matteodo, S. Di Giulio, Paola Facheris, Luciano Ibba, Chiara Perugini, Mario Valenti, Carlo Alberto Vignoli, Antonio Costanzo, Alessandra Narcisi, Luigi Gargiulo

    出版 2025
    获取全文
    Revisão
    加到收藏夹
    Saved in:
  17. 17
    Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study—<scp>IL PSO</scp> (<scp>Italian landscape psoriasis</scp>)

    Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study—<scp>IL PSO</scp> (<scp>Italian landscape psoriasis</scp>) 由 Alessandra Narcisi, Mario Valenti, Luigi Gargiulo, Luciano Ibba, Fabrizio Amoruso, Giuseppe Argenziano, Federico Bardazzi, Martina Burlando, Carlo Giovanni Carrera, Giovanni Damiani, Paolo Dapavo, Valentina Dini, Chiara Franchi, Giampiero Girolomoni, Claudio Guarneri, Francesco Loconsole, Francesca Sampogna, Massimo Travaglini, Piergiorgio Malagoli, Antonio Costanzo

    出版 2022
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  18. 18
    Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study – IL PSO (Italian landscape psoriasis)

    Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study – IL PSO (Italian landscape psoriasis) 由 Mario Valenti, Luciano Ibba, S. Di Giulio, Luigi Gargiulo, Piergiorgio Malagoli, Anna Balato, Carlo Giovanni Carrera, Paolo Dapavo, Eugenia Veronica Di Brizzi, Valentina Dini, Francesca Maria Gaiani, Francesco Loconsole, Angelo Valerio Marzano, Matteo Megna, Alessandra Michelucci, Luca Potestio, Simone Ribero, Antonio Costanzo, Alessandra Narcisi

    出版 2025
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  19. 19
    Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses – IL PSO (Italian landscape psoriasis)

    Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses – IL PSO... 由 Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Anna Balato, Federico Bardazzi, Martina Burlando, Carlo Giovanni Carrera, Giovanni Damiani, Paolo Dapavo, Valentina Dini, Francesca Maria Gaiani, Giampiero Girolomoni, Claudio Guarneri, Claudia Lasagni, Francesco Loconsole, Angelo Valerio Marzano, Matteo Megna, Santo Raffaele Mercuri, Massimo Travaglini, Antonio Costanzo, Alessandra Narcisi

    出版 2024
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  20. 20
    Real‐life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104‐week multicenter retrospective study – <scp>IL PSO</scp> (<scp>ITALIAN LANDSCAPE PSORIASIS</scp>)

    Real‐life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104‐week multicenter retrospective study – <scp>IL PSO... 由 Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Rosa Giuseppa Angileri, Federico Bardazzi, Nicoletta Bernardini, Martina Burlando, Carlo Giovanni Carrera, Andrea Chiricozzi, Paolo Dapavo, Valentina Dini, Gabriella Fabbrocini, Francesca Maria Gaiani, Marco Galluzzo, Claudia Giofrè, Claudio Guarneri, Francesco Loconsole, Giovanna Malara, Lorenzo Marcelli, Matteo Megna, Stefano Piaserico, Mark S. Talamonti, Antonio Costanzo, Alessandra Narcisi

    出版 2023
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: